Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Kato, Yukihiko; Egusa, Chizu; Maeda, Tatsuo; Tsuboi, Ryoji
• Is Part Of: Journal of dermatological science. Volume 81:Issue 1(2016:Jan.)
• Page Start: 17
• Page End: 25
• Publication Date: 2016-01
• Subjects: RAR retinoic acid receptor -- CTCL cutaneous T cell lymphoma -- HDAC histone deacetylase -- RXR retinoid X receptors; Retinoic acid receptor -- Cutaneous T cell lymphoma -- Histone acetylation -- DNA methylation; Dermatology -- Periodicals; Skin Diseases -- Periodicals; Dermatologie -- Périodiques; 616.5005
• DOI: 10.1016/j.jdermsci.2015.10.016
• Languages: English
• ISSNs: 0923-1811

Abstract

Highlights: Tumor suppressor gene, retinoic acid receptor β2 (RARβ2), was suppressed in CTCL. The combination of retinoid with histone acetylation agent restored RARβ2 in CTCL. The combination treatment inhibited cell growth by apoptosis in vitro. The combination treatment suppressed tumor growth and prolonged survival in vivo. This is first report of histone acetylation as primary in restoration of RARβ2. Abstract: Background: Retinoids exert anti-proliferative, differentiative, and apoptosis-inducing effects through their receptors. Retinoic acid receptor (RAR) β2 behaves as a tumor suppressor gene, and its expression is suppressible by DNA methylation in many malignancies. Objective: We aimed to determine whether combining a retinoid, Am 80, with a histone deacetylase inhibitor, MS-275, could suppress tumor growth in a RARβ2-negative human cutaneous T cell lymphoma (CTCL) cell lines and freshly isolated primary CTCL cells, and to elucidate the epigenetic mechanism behind the phenomena. Methods: SeAx cells were implanted subcutaneously in NOD-SCID mice which were randomly divided into four groups and treated with either Am80, MS-275 by oral gavage (five days/week), or a combination of the two agents. Cell proliferation assay, methylation-specific PCR, flow cytometric analysis of cell cycle and apoptosis and chromatin immunoprecipitation assay were employed. Results: Quantitative PCR analysis revealed that RARβ2 gene expression was restored only by this combination rather than by either of the agents singly. Restored retinoid sensitivity was observed in combining retinoid with a histone deacetylase inhibitor significantly inhibited cell growth in vitro, suppressed subcutaneously transplanted tumor growth, and prolonged survival of tumor-bearing mice in vivo by more strongly inducing apoptosis and p21 expression in CTCL cells than either agent alone. In the combination treatment, the histone H4 acetylation level at lysine 12 and 16 in the promoter region increased after restoration of RARβ2 expression although the DNA methylation of RARβ2 remained unchanged. Conclusion: This is the first report of histone acetylation as the primary event in the restoration of RARβ2. Inducible RARβ2 expression may serve as a reliable predictor for tumor response in patients undergoing 'epigenetic & differentiation' therapy.